AstraZeneca is selling rights to its heart failure and hypertension brand Atacand in Europe, in a move that it says will expand its commercial potential in 28 countries.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.